Evidence map›Paper›PMID 40980915›Full record

ArticleAntimicrobial agents and chemotherapy2025

Thienopyrimidine amide analogs target MmpL3 in

Vanessa Pietrowski Baldin, Christopher L Harding, Diana Quach, Joseph Sugie, Joe Pogliano, Tanya Parish

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Vanessa Pietrowski BaldinCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0002-4200-6254
Christopher L HardingCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Diana QuachLinnaeus Bioscience, Inc, San Diego, California, USA.
Joseph SugieLinnaeus Bioscience, Inc, San Diego, California, USA.
Joe PoglianoLinnaeus Bioscience, Inc, San Diego, California, USA.
Tanya ParishCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-7507-0423

Funding

Targeting protein secretion in Mycobacterium tuberculosisR01AI182006 · NIAID · TMLIVERPOOL SCHOOL OF TROPICAL MEDICINE · PI Tanya Parish · 2024 to 2026
$2.2M
NIAID NIH HHS R01 AI182006NIH HHS R01AI182006U.S. Department of Defense PR180794
6 · The paper itself

Abstract

The identification of novel agents with mechanisms of action distinct from those currently utilized in tuberculosis treatment remains a significant challenge. The mycobacterial protein MmpL3 has emerged as a promising drug target due to its essential role in the synthesis of the cell wall of

Indexed as

AmidesAntitubercular AgentsBacterial ProteinsMycobacterium tuberculosisPyrimidinesAdenosine TriphosphateCell WallHumansMembrane Transport ProteinsMicrobial Sensitivity TestsMutationAdenosine TriphosphateAmidesAntitubercular AgentsBacterial ProteinsMembrane Transport ProteinsMmpL3 protein, Mycobacterium tuberculosisPyrimidinesantitubercularcell wall biosynthesisdrug discoverydrug targettuberculosis

Identifiers

PMID40980915
PMCPMC12587563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.